Cost-effective way to be up-to-date about newly published or initiated health technology assessment projects for medical devices by more than 100 European HTA bodies
Get customized reports monthly to your e-mail
Service goes global
We provide full range of services to path the way for your technology in European countries: from market access strategy to economic modelling and reimbursement dossier


Mar 24, 2015

Clinical commissioning policy determines framework for provision (target population, conditions, funding mechanisms, quality requirements) of the services in England. Current call for consultations covers bariatric surgery, PET-CT, proton beam radiotherapy, robot-assisted surgical procedures for cancer, cervical disk replacement, microprocessor-controlled knee prosthesis, deep brain stimulation for epilepsy and chronic pain, intrathecal pumps, genetic testing for BRCA1 and BRCA2 mutations, sacral nerve stimulation for urinary incontinence. 

Mar 23, 2015

As we informed you last year in a post, there is an on-going change in Germany regarding

Mar 19, 2015

Decree of the Russian Government #102 of 05.02.2015 has established restrictions for procurement of certain types of medical devices, manufactured abroad, when at least two analogues, manufactured in Armenia, Belarus, Kazakhstan and Russia, are available. This Decree regulates access to all procurements for public health care system.


Mar 23, 2015

The outcomes from the 32 IVD’s HTAs have scattered results. In total, only six (19%) has clear positive recommendations. The remaining had either positive with restrictions, no conclusion or negative.

Jan 30, 2015

The German DRG institute have now published the new list with NUBs valid for 2015. Based on our analysis we identified 5 new products that have received category 1 for the first time. This is the category that enables the hospital to negotiate for innovation funding.

Dec 30, 2014

In total 23 out of 36 published HTA reports considered health economic data.The most common method of analysis was cost-effectiveness and cost-utility analysis. Majority of the studies (65%) conducted systematic review or de novo health economic analysis.